Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer

NCT ID NCT06526299

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells to damage their DNA. It is for people with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this treatment can slow cancer growth and improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Olive View-University of California Los Angeles Medical Center

    NOT_YET_RECRUITING

    Sylmar, California, 91342, United States

    Contact

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.